Q-omics provides the consensus-scored FAM217A profile across patient tissues and cancer cell-line models. FAM217A expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM217A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, FAM217A RNA expression shows 18,397 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where FAM217A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM217A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM217A survival associations across molecular data types. FAM217A RNA expression shows survival associations in the most cancer types (17), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM217A RNA expression–survival associations across cancer types. High FAM217A expression shows unfavorable associations in UVM, KIRP, DLBC and CHOL, but favorable associations in LAML and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAM217A RNA expression.
This table summarizes FAM217A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM217A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM217A shows lower tumor expression in KIRC, KICH, KIRP and THCA and higher tumor expression in BLCA and LIHC. The KIRC box plot shows higher FAM217A RNA expression in normal versus tumor tissue (log2 FC = −0.449, t-test p < 0.001).
This table shows molecular features associated with FAM217A in patient tissues and cancer cell lines. In patient samples, FAM217A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM217A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
